244 related articles for article (PubMed ID: 23993384)
1. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
Lin NU; Lee EQ; Aoyama H; Barani IJ; Baumert BG; Brown PD; Camidge DR; Chang SM; Dancey J; Gaspar LE; Harris GJ; Hodi FS; Kalkanis SN; Lamborn KR; Linskey ME; Macdonald DR; Margolin K; Mehta MP; Schiff D; Soffietti R; Suh JH; van den Bent MJ; Vogelbaum MA; Wefel JS; Wen PY;
Lancet Oncol; 2013 Sep; 14(10):e396-406. PubMed ID: 23993384
[TBL] [Abstract][Full Text] [Related]
2. Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
Lin NU; Wefel JS; Lee EQ; Schiff D; van den Bent MJ; Soffietti R; Suh JH; Vogelbaum MA; Mehta MP; Dancey J; Linskey ME; Camidge DR; Aoyama H; Brown PD; Chang SM; Kalkanis SN; Barani IJ; Baumert BG; Gaspar LE; Hodi FS; Macdonald DR; Wen PY;
Lancet Oncol; 2013 Sep; 14(10):e407-16. PubMed ID: 23993385
[TBL] [Abstract][Full Text] [Related]
3. Response assessment criteria for brain metastases: proposal from the RANO group.
Lin NU; Lee EQ; Aoyama H; Barani IJ; Barboriak DP; Baumert BG; Bendszus M; Brown PD; Camidge DR; Chang SM; Dancey J; de Vries EG; Gaspar LE; Harris GJ; Hodi FS; Kalkanis SN; Linskey ME; Macdonald DR; Margolin K; Mehta MP; Schiff D; Soffietti R; Suh JH; van den Bent MJ; Vogelbaum MA; Wen PY;
Lancet Oncol; 2015 Jun; 16(6):e270-8. PubMed ID: 26065612
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Alexander BM; Brown PD; Ahluwalia MS; Aoyama H; Baumert BG; Chang SM; Gaspar LE; Kalkanis SN; Macdonald DR; Mehta MP; Soffietti R; Suh JH; van den Bent MJ; Vogelbaum MA; Wefel JS; Lee EQ; Wen PY;
Lancet Oncol; 2018 Jan; 19(1):e33-e42. PubMed ID: 29304360
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Camidge DR; Lee EQ; Lin NU; Margolin K; Ahluwalia MS; Bendszus M; Chang SM; Dancey J; de Vries EGE; Harris GJ; Hodi FS; Lassman AB; Macdonald DR; Peereboom DM; Schiff D; Soffietti R; van den Bent MJ; Wefel JS; Wen PY
Lancet Oncol; 2018 Jan; 19(1):e20-e32. PubMed ID: 29304358
[TBL] [Abstract][Full Text] [Related]
6. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
[TBL] [Abstract][Full Text] [Related]
7. Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.
Huang RY; Wen PY
Magn Reson Imaging Clin N Am; 2016 Nov; 24(4):705-718. PubMed ID: 27742111
[TBL] [Abstract][Full Text] [Related]
8. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
van den Bent MJ; Wefel JS; Schiff D; Taphoorn MJ; Jaeckle K; Junck L; Armstrong T; Choucair A; Waldman AD; Gorlia T; Chamberlain M; Baumert BG; Vogelbaum MA; Macdonald DR; Reardon DA; Wen PY; Chang SM; Jacobs AH
Lancet Oncol; 2011 Jun; 12(6):583-93. PubMed ID: 21474379
[TBL] [Abstract][Full Text] [Related]
9. Imaging Criteria in Neuro-oncology.
Nowosielski M; Wen PY
Semin Neurol; 2018 Feb; 38(1):24-31. PubMed ID: 29548049
[TBL] [Abstract][Full Text] [Related]
10. Response Assessment in Neuro-Oncology Clinical Trials.
Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
[TBL] [Abstract][Full Text] [Related]
11. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.
Lin NU; Prowell T; Tan AR; Kozak M; Rosen O; Amiri-Kordestani L; White J; Sul J; Perkins L; Beal K; Gaynor R; Kim ES
J Clin Oncol; 2017 Nov; 35(33):3760-3773. PubMed ID: 28968165
[TBL] [Abstract][Full Text] [Related]
12. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
13. Comparing available criteria for measuring brain metastasis response to immunotherapy.
Qian JM; Mahajan A; Yu JB; Tsiouris AJ; Goldberg SB; Kluger HM; Chiang VLS
J Neurooncol; 2017 May; 132(3):479-485. PubMed ID: 28275886
[TBL] [Abstract][Full Text] [Related]
14. Evolution of RANO in Assessing Brain Tumour Outcomes.
Virani QU; Javed Z; Shamim MS
J Pak Med Assoc; 2024 Mar; 74(3):595-596. PubMed ID: 38591309
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Brain Tumor Response: RANO and Its Offspring.
Eisele SC; Wen PY; Lee EQ
Curr Treat Options Oncol; 2016 Jul; 17(7):35. PubMed ID: 27262709
[TBL] [Abstract][Full Text] [Related]
16. Update on amino acid PET of brain tumours.
Langen KJ; Galldiks N
Curr Opin Neurol; 2018 Aug; 31(4):354-361. PubMed ID: 29952832
[TBL] [Abstract][Full Text] [Related]
17. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
Singh C; Qian JM; Yu JB; Chiang VL
J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.
Galanis E; Wu W; Cloughesy T; Lamborn K; Mann B; Wen PY; Reardon DA; Wick W; Macdonald D; Armstrong TS; Weller M; Vogelbaum M; Colman H; Sargent DJ; van den Bent MJ; Gilbert M; Chang S
Lancet Oncol; 2012 May; 13(5):e196-204. PubMed ID: 22554547
[TBL] [Abstract][Full Text] [Related]
19. Brain metastases: old problem, new strategies.
Nguyen TD; Abrey LE
Hematol Oncol Clin North Am; 2007 Apr; 21(2):369-88. PubMed ID: 17512454
[TBL] [Abstract][Full Text] [Related]
20. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
Sharma M; Juthani RG; Vogelbaum MA
Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
